ReviewVeterinary research forum : an international quarterly journal2015
An overview on Leishmania vaccines: A narrative review article.
Review in Veterinary research forum : an international quarterly journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 62 citations in OpenAlex.
- Evaluation ofMicrobiology spectrum · 2025Article
- Recombinant Leishmania-activated C kinase as a novel antigenic candidate for immuno-diagnosis of visceral leishmaniasis occurring in India and Brazil.Infectious diseases of poverty · 2025Article
- Multi-epitope vaccine design against leishmaniasis using IFN-γ inducing epitopes from immunodominant gp46 and gp63 proteins.Journal, genetic engineering & biotechnology · 2024Article
- Aminoacyl tRNA Synthetases: Implications of Structural Biology in Drug Development against Trypanosomatid Parasites.ACS omega · 2023Review
- The History of Live AttenuatedPathogens (Basel, Switzerland) · 2022Review
- GC-MS screening and antiparasitic action ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021Article
- LmjF.36.3850, a novel hypothetical Leishmania major protein, contributes to the infection.Immunology · 2021Article
- Sphingomyelin liposome bearing wholeIranian journal of basic medical sciences · 2021Article
- Establishment, optimisation and quantitation of a bioluminescent murine infection model of visceral leishmaniasis for systematic vaccine screening.Scientific reports · 2020Article
- SuicidalPathogens (Basel, Switzerland) · 2020Article
- Therapeutic Interventions for Countering Leishmaniasis and Chagas's Disease: From Traditional Sources to Nanotechnological Systems.Pathogens (Basel, Switzerland) · 2019Review
- Article
- Review
- Nonconventional opponents: a review of malaria and leishmaniasis among United States Armed Forces.PeerJ · 2019Article
- Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies AgainstFrontiers in immunology · 2018Review
- Peptide Vaccines for Leishmaniasis.Frontiers in immunology · 2018Review
- Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is one of the major health problems and categorized as a class I disease (emerging and uncontrolled) by World Health Organization (WHO), causing highly significant morbidity and mortality. Indeed, more than 350 million individuals are at risk of Leishmania infection, and about 1.6 million new cases occur causing more than 50 thousands death annually. Because of the severe toxicity and drug resistance, present chemotherapy regimen against diverse forms of Leishmania infections is not totally worthwhile. However, sound immunity due to natural infection, implies that vigor cellular immunity against Leishmania parasites, via their live, attenuated or killed forms, can be developed in dogs and humans. Moreover, genetically conserved antigens (in most of Leishmania species), and components of sand fly saliva confer potential immunogenic molecules for Leishmania vaccination. Vaccines successes in animal studies and some clinical trials clearly justify more researches and investments illuminating opportunities in suitable vaccine designation.
Indexed as
Identifiers
25992245PMC4405679W1717875263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.